Clinical Outcomes for Patients with Acute Myeloid Leukemia Harboring IDH1 Mutation After Intensive Chemotherapy.
- Resource Type
- Article
- Authors
- Azzazi, Mohamed O.; El Salakawy, Walaa A.; Saweris, John A.; Abdalla, Nour El Hoda H.
- Source
- Egyptian Journal of Hospital Medicine. Jul2022, Vol. 88, p3089-3093. 5p.
- Subject
- *ACUTE myeloid leukemia
*TREATMENT effectiveness
*ISOCITRATE dehydrogenase
*GENETIC mutation
*MYELOID cells
*PRELEUKEMIA
- Language
- ISSN
- 1687-2002
Background: Acute myeloid leukemia (AML) is heterogeneous myeloid disorder with multifactorial pathogenic mechanisms and a broad range of prognosis. AML is characterized by clonal proliferation of poorly differentiated cells of the myeloid lineage. Objective: This study aimed to detect Isocitrate Dehydrogenase 1 (IDH1) mutation in adult Egyptian AML patients and to find correlation between the mutation and prognosis & survival in those patients after intensive chemotherapy. Patients and Methods: Our study included 98 subjects with newly diagnosed AML. They all presented to Ain Shams University Hospital (Hematology Unit). All Patients included in the study were subjected to: History taking and clinical examination, laboratory investigations including routine investigations and cytogenetic studies for detection of IDH 1 mutation. All patients were followed up for their response to treatment for a period of 6 months. Results: IDH1 mutation occurs in a considerable percentage of Egyptian AML patients that shows independent bad prognostic impact on the clinical outcome. Conclusion: IDH1 mutation occurred in a considerable percentage of Egyptian AML patients that showed independent bad prognostic impact on the clinical outcome. [ABSTRACT FROM AUTHOR]